Glucokinase activator 3
Based on 1 Customer Validation
Glucokinase activator 3 is an orally active Glucokinase (GK) activator with an AC50 of 38 nM. Glucokinase activator 3 inhibits hERG channel and sodium channel in patch clamp assays. Glucokinase activator 3 exhibits high efficacy in reducing blood glucose in diet-induced obese (DIO) mice. Glucokinase activator 3 has the potential for the research of type 2 diabetes.
For research use only. We do not sell to patients.
- Purity : 98.36%
- CAS No.: 1001417-92-0
- Formula: C26H33N2O9PS2
- Molecular Weight:612.65
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
AC50: 38 nM (GK)[1]
In Vitro
Glucokinase activator 3 (Compound 11) (10 μM) inhibits hERG channel by 60% and sodium channel by 40% in patch clamp assays[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:DIO mice were established by maintaining normal C57BL/6J mice on a high-fat diet (HFD) for several weeks, which rendered the mice glucose-intolerant, hyperinsulinemic, and insulin-resistant but not diabetic[1]
-
Dosage:1.83 mg/kg (3 μmol/kg)
-
Administration:p.o. for a single dose
-
Result:Showed highly efficacious in lowering glucose in an oral glucose tolerance test (OGTT).
Chemical Information
-
CAS No. 1001417-92-0
-
Appearance Solid
-
Molecular Weight 612.65
-
Formula C26H33N2O9PS2
-
Color White to off-white
-
SMILES
O=C(NC1=NC(CP(OCC)(OCC)=O)=CS1)C2=CC(OC3=CC=C(S(=O)(C)=O)C=C3)=CC(O[C@@H](C)COC)=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (163.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Synaptic current patch-clamp recording in brain slices
Whole-cell patch-clamp recording in acute brain slices measures membrane current from visually identified neurons while preserving part of the local synaptic circuit; in voltage clamp, postsynaptic currents are generated by synaptic receptor-channel activation and are recorded as inward or outward currents at a defined holding potential. Miniature synaptic currents are recorded during action-potential blockade with tetrodotoxin, whereas evoked synaptic currents are generated by pathway stimulation and isolated pharmacologically as EPSCs or IPSCs.
-
Acute brain-slice whole-cell patch-clamp recording
Acute brain-slice whole-cell patch-clamp recording measures membrane voltage or ionic current from visually targeted cells in living brain slices; after giga-seal formation, the membrane under the pipette is ruptured to provide low-resistance electrical access to the cell interior, enabling current-clamp analysis of excitability and voltage-clamp analysis of synaptic or membrane currents. Acute slices preserve local tissue architecture better than dissociated preparations and allow visually guided recording from defined brain regions or fluorescently labeled cells; however, whole-cell access also permits exchange between pipette solution and cytoplasm, so intracellular dialysis must be considered when interpreting signaling-dependent phenomena.
-
Cell-attached patch-clamp recording
Cell-attached patch-clamp recording measures ionic current through one or more ion channels in a small membrane patch that remains attached to an intact cell; the readout is a time-resolved current trace generated when channels in the sealed patch open and close under controlled pipette voltage or stimulus conditions. Classic applications include single acetylcholine receptor currents in frog skeletal muscle, single sodium-channel currents in cultured rat muscle cells, one-channel NMDA receptor recordings, and mechanically activated PIEZO-channel recordings. The method depends on forming a high-resistance pipette-membrane seal, commonly described as a gigaohm seal, which reduces leak and noise sufficiently to resolve picoampere-scale single-channel currents. In the cell-attached configuration, the patch membrane is not ruptured, so cytosolic composition is not directly dialyzed by the pipette solution.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6323 mL | 8.1613 mL | 16.3225 mL | 40.8063 mL |
| 5 mM | 0.3265 mL | 1.6323 mL | 3.2645 mL | 8.1613 mL | |
| 10 mM | 0.1632 mL | 0.8161 mL | 1.6323 mL | 4.0806 mL | |
| 15 mM | 0.1088 mL | 0.5441 mL | 1.0882 mL | 2.7204 mL | |
| 20 mM | 0.0816 mL | 0.4081 mL | 0.8161 mL | 2.0403 mL | |
| 25 mM | 0.0653 mL | 0.3265 mL | 0.6529 mL | 1.6323 mL | |
| 30 mM | 0.0544 mL | 0.2720 mL | 0.5441 mL | 1.3602 mL | |
| 40 mM | 0.0408 mL | 0.2040 mL | 0.4081 mL | 1.0202 mL | |
| 50 mM | 0.0326 mL | 0.1632 mL | 0.3265 mL | 0.8161 mL | |
| 60 mM | 0.0272 mL | 0.1360 mL | 0.2720 mL | 0.6801 mL | |
| 80 mM | 0.0204 mL | 0.1020 mL | 0.2040 mL | 0.5101 mL | |
| 100 mM | 0.0163 mL | 0.0816 mL | 0.1632 mL | 0.4081 mL |